CURE’s breast cancer page is an extensive resource of cancer information featuring the latest breast cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on breast cancer.
September 27th 2024
As a caregiver to my daughter who had breast cancer, pink takes on a new meaning for us — one I’m not quite a fan of.
September 25th 2024
September 23rd 2024
September 18th 2024
Pre-Surgical Keytruda Provides Promising Advancement in TNBC Treatment
December 20th 2021Findings from a clinical trial showed that adding Keytruda to neoadjuvant chemotherapy in patients with triple-negative breast cancer significantly improved outcomes and was overall safe and tolerable for patients.
Lynparza After Chemo May Not Greatly Impact Quality of Life in High-Risk Early Breast Cancer Subset
December 11th 2021Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.
Experimental Drug Plus Chemo Boosts Survival in HER2-Positive Metastatic Breast Cancer
December 10th 2021The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.
Immunotherapy Before Surgery May ‘Increase the Chances’ Patients Are Cured of TNBC
December 9th 2021Clinical trial results show that adding Keytruda to chemotherapy prior to surgery for triple-negative breast cancer can improve outcomes and hopefully “increase the chances for patients to be cured,” according to an expert.
Study Confirms Adding Ibrance to Endocrine Therapy May Not Improve Outcomes in Early Breast Cancer
December 8th 2021The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
Novel Drug Has Potential to ‘Become New Standard of Care’ in Advanced, ER-Positive Breast Cancer
December 8th 2021The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.